Skip to content

Clinical trials

Carcinoma, Hepatocellular trials with no applicable phase and unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Hepatocellular Phase: Not applicable Status: Unknown status Clear all

177 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20041
20051
20073
20081
20093
20103
20116
20124
20135
20143
201512
201616
201716
201818
201915
202020
202117
202210
202314
20245

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status177

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Seoul National University Hospital15
Sun Yat-sen University9
Eastern Hepatobiliary Surgery Hospital8
Southwest Hospital, China7
Fudan University4
Huazhong University of Science and Technology4
Second Affiliated Hospital, Zhejiang University, School of Medicine4
Shanghai Zhongshan Hospital4
Assistance Publique - Hôpitaux de Paris3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Hepatocellular177
Liver Neoplasms17
Liver Cirrhosis12
Recurrence11
Fibrosis8
Liver Diseases3
Pancreatic Neoplasms3
Cholangiocarcinoma2
Hepatitis B, Chronic2
Hepatitis C2

Trials

Showing 1 to 25 of 177. Each trial links to its page on Pharma Observatory.

77 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.